APA
Joshi A. D., Botham R. C., Schlein L. J., Roth H. S., Mangraviti A., Borodovsky A., Tyler B., Joslyn S., Looper J. S., Podell M., Fan T. M., Hergenrother P. J. & Riggins G. J. (2017). Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. : Oncotarget.
Chicago
Joshi Avadhut D, Botham Rachel C, Schlein Lisa J, Roth Howard S, Mangraviti Antonella, Borodovsky Alexandra, Tyler Betty, Joslyn Steve, Looper Jayme S, Podell Michael, Fan Timothy M, Hergenrother Paul J and Riggins Gregory J. 2017. Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. : Oncotarget.
Harvard
Joshi A. D., Botham R. C., Schlein L. J., Roth H. S., Mangraviti A., Borodovsky A., Tyler B., Joslyn S., Looper J. S., Podell M., Fan T. M., Hergenrother P. J. and Riggins G. J. (2017). Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. : Oncotarget.
MLA
Joshi Avadhut D, Botham Rachel C, Schlein Lisa J, Roth Howard S, Mangraviti Antonella, Borodovsky Alexandra, Tyler Betty, Joslyn Steve, Looper Jayme S, Podell Michael, Fan Timothy M, Hergenrother Paul J and Riggins Gregory J. Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients. : Oncotarget. 2017.